ProCE Banner Activity

EV-103 Cohort K: Enfortumab Vedotin ± Pembrolizumab in Untreated Cisplatin-Ineligible Patients With Locally Advanced/Metastatic Urothelial Carcinoma

Slideset Download
Conference Coverage
Results from cohort K of the phase I/II EV-103 study evaluating enfortumab vedotin with or without pembrolizumab as first-line treatment in patients with advanced or metastatic UC who are ineligible for cisplatin showed promising efficacy and a manageable safety profile.

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.